New Diabetes Drugs in 2008: GLP-1 Agonists, DPP-4 Inhibitors, and the New Treatment Era
GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin) represent major new diabetes drug classes, with weight loss benefits and low hypoglycemia risk distinguishing them from existing therapies.
Quick Facts
What This Study Found
New diabetes drugs include GLP-1 agonists (exenatide, liraglutide: injectable, weight loss, low hypo risk), DPP-4 inhibitors (sitagliptin, vildagliptin: oral, weight neutral), and amylin analog (pramlintide) — peptide-based drugs transforming type 2 diabetes treatment.
Key Numbers
How They Did This
review study.
Why This Research Matters
Relevant for glp-1, diabetes, semaglutide, tirzepatide.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding New diabetes drugs include GLP-1 agonists (exenatide, liraglutide: injectable, weight loss, low hypo risk), DPP-4 inhibitors (sitagliptin, vildaglipti
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2008.
- Original Title:
- New drugs for type 2 diabetes mellitus: what is their place in therapy?
- Published In:
- Drugs, 68(15), 2131-62 (2008)
- Authors:
- Krentz, Andrew J, Patel, Mayank B, Bailey, Clifford J(5)
- Database ID:
- RPEP-01370
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What was studied?
New Diabetes Drugs in 2008: GLP-1 Agonists, DPP-4 Inhibitors, and the New Treatment Era
What was found?
GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin) represent major new diabetes drug classes, with weight loss benefits and low hypoglycemia risk distinguishing them from existing therapies.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01370APA
Krentz, Andrew J; Patel, Mayank B; Bailey, Clifford J. (2008). New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs, 68(15), 2131-62.
MLA
Krentz, Andrew J, et al. "New drugs for type 2 diabetes mellitus: what is their place in therapy?." Drugs, 2008.
RethinkPeptides
RethinkPeptides Research Database. "New drugs for type 2 diabetes mellitus: what is their place ..." RPEP-01370. Retrieved from https://rethinkpeptides.com/research/krentz-2008-new-drugs-for-type
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.